Results 51 to 60 of about 19,722 (182)

Development of protein degradation inducers of oncogenic BCR‐ABL protein by conjugation of ABL kinase inhibitors and IAP ligands

Cancer Science, 2017
Chromosomal translocation occurs in some cancer cells, which results in the expression of aberrant oncogenic fusion proteins that include BCR‐ABL in chronic myelogenous leukemia (CML).
N. Shibata, Naoki Miyamoto, Katsunori Nagai, K. Shimokawa, Tomoya Sameshima, Nobumichi Ohoka, T. Hattori, Y. Imaeda, H. Nara, N. Cho, M. Naito   +10 more
semanticscholar   +1 more source

Apoptosis resistance in chronic myelogenous leukemia [PDF]

Einstein (São Paulo), 2005
The chronic myeloid leukemia (CML) is the three-phasemyeloproliferative disorder, dependent on the expression of theoncoprotein Bcr-Abl, which is the product of the reciprocaltranslocation between chromosomes 9 and 22, resulting in thePhiladelphia ...
Fabíola Attié de Castro, Jacqueline de Fátima Jacysyn, Ana Elisa Bueno-da-Silva, Nelson Hamerschlak, Gustavo Pessini Amarante-Mendes   +4 more
doaj  

Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor β gene

Haematologica, 2007
Background and Objectives We sought to identify new fusion genes with involvement of the platelet-derived growth factor receptor β gene (PDGFRB) in three patients presenting with various subtypes of chronic myeloproliferative disorders associated with ...
Christoph Walz, Georgia Metzgeroth, Claudia Haferlach, Annette Schmitt-Graeff, Alice Fabarius, Volker Hagen, Otto Prümmer, Stefan Rauh, Rüdiger Hehlmann, Andreas Hochhaus, Nicholas C.P. Cross, Andreas Reiter   +11 more
doaj   +1 more source

High‐throughput screening identifies bazedoxifene as a potential therapeutic for dysferlin‐deficient limb girdle muscular dystrophy

British Journal of Pharmacology, Volume 182, Issue 13, Page 2930-2949, July 2025.
Abstract Background and Purpose Limb‐girdle muscular dystrophy R2 (LGMD R2) is a rare genetic disorder characterised by progressive weakness and wasting of proximal muscles. LGMD R2 is caused by the loss of function of dysferlin, a transmembrane protein crucial for plasma membrane repair in skeletal muscles.
Celine Bruge, Nathalie Bourg, Emilie Pellier, Johana Tournois, Jerome Polentes, Manon Benabides, Noella Grossi, Anne Bigot, Anthony Brureau, Isabelle Richard, Xavier Nissan   +10 more
wiley   +1 more source

Differential Signaling through p190 and p210 Forms of BCR-ABL Fusion Proteins Revealed By Proteomic Analysis

Blood, 2015
Abstract Chromosomal translocations involving chromosome 9q34 and 22q11 generate the BCR-ABL1 fusion gene. The location of the translocation within the BCR gene dictates which exons are excluded or included in the resulting fusion with the ABL1 gene.
Rahia Tahir, Saradhi Mallampati, Akhilesh Pandey, Xiaoping Sun, Patrick Brown, Jingnan Han, Xianrong Wong, Karen L. Reddy, Jevon Cutler, Tai-Chung Huang, Raja Sekhar Nirujogi   +10 more
openaire   +2 more sources

c-Fos and Dusp1 confer non-oncogene addiction in BCR-ABL induced leukemia

Nature Network Boston, 2017
Tyrosine-kinase inhibitor (TKI) therapy for human cancers is not curative, and relapse occurs owing to the continued presence of tumor cells, referred to as minimal residual disease (MRD).
M. Kesarwani, Zachary Kincaid, A. Gomaa, E. Huber, Sara L. Rohrabaugh, Z. Siddiqui, Muhammad F Bouso, T. Latif, Ming-zheng Xu, K. Komurov, J. Mulloy, J. Cancelas, H. Grimes, M. Azam   +13 more
semanticscholar   +1 more source

Integration of Optical Genome Mapping in the Cytogenomic and Molecular Work‐Up of Hematological Malignancies: Expert Recommendations From the International Consortium for Optical Genome Mapping

American Journal of Hematology, Volume 100, Issue 6, Page 1029-1048, June 2025.
ABSTRACT The latest updates to the classification of hematolymphoid malignancies using the World Health Organization (WHO, 5th ed.) and ICC (International Consensus Classification) criteria highlight the critical need for comprehensive and precise cytogenomic data for diagnosis, prognostication, and treatment.
Rashmi Kanagal‐Shamanna, Anna Puiggros, Isabel Granada, Gordana Raca, Katrina Rack, Mar Mallo, Barbara Dewaele, Adam C. Smith, Yassmine Akkari, Brynn Levy, Robert P. Hasserjian, Adela Cisneros, Marta Salido, Guillermo Garcia‐Manero, Hui Yang, M. Anwar Iqbal, Ravindra Kolhe, Francesc Solé, Blanca Espinet   +18 more
wiley   +1 more source

Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein.

Chemical and pharmaceutical bulletin, 2019
Chromosomal translocation occurs in some cancer cells, resulting in the expression of aberrant oncogenic fusion proteins that include BCR-ABL in chronic myelogenous leukemia (CML).
N. Shibata, Nobumichi Ohoka, T. Hattori, M. Naito   +3 more
semanticscholar   +1 more source

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells

Tumor Biology, 2017
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance ...
Alphy Rose James, BS Unnikrishnan, R Priya, Manu M Joseph, TK Manojkumar, K Raveendran Pillai, R Shiji, GU Preethi, P Kusumakumary, TT Sreelekha   +9 more
doaj   +1 more source

Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia

Cells, 2019
Leukemias bearing mixed lineage leukemia (MLL) rearrangement (MLL-R) resulting in expression of oncogenic MLL fusion proteins (MLL-FPs) represent an especially aggressive disease subtype with the worst overall prognoses and chemotherapeutic response. MLL-
Aditya Barve, Alexis Vega, Parag P. Shah, Smita Ghare, Lavona Casson, Mark Wunderlich, Leah J. Siskind, Levi J. Beverly   +7 more
doaj   +1 more source